New data on patient treatment satisfaction from the LEAD 6 trial presented at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide.
The details can be read here.
No comments:
Post a Comment